BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences.
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - President and CEO Steve Griffin - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome t...
WEST BRIDGEWATER, Mass. , Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK).
Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds
Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile
BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common sto...
BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.15, which equaled the closing price of common ...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.